Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The genomic landscape of HER2 negative metastatic breast cancer with loss of estrogen and progesterone receptors.

Breast (Edinburgh, Scotland) - 1 Oct 2026

Migliaccio Ilenia, Paoli Marta, Biagioni Chiara, Guarducci Cristina, Galardi Francesca, Anichini Giulia, Biganzoli Laura, Benelli Matteo, Malorni Luca

Abstract excerpt

INTRODUCTION: Loss of estrogen receptor (ER) and/or progesterone receptor (PR) might occur during the metastatic progression of ER positive and HER2 negative (ER+/HER2-) breast cancer (BC), but the underpinning molecular alterations remain elusive. We explored the genomic context of HER2- tumors with ER and/or PR loss to investigate potential drivers and actionable alterations that might help personalize...

Read the complete abstract on PubMed

Topics

Humans
Female
Receptors, Progesterone
Breast Neoplasms
Erb-b2 Receptor Tyrosine Kinases
Receptors, Estrogen

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Middle Aged

Mutation

GATA3 Transcription Factor

Class I Phosphatidylinositol 3-Kinases

Adult

Biomarkers, Tumor

Aged

Genomics

Neoplasm Metastasis

Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 42673686
DOI: 10.1016/j.breast.2026.104897
PMCID: PMC13562660

Genes

ESR1
GATA3
PIK3CA
RB1
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The genomic landscape of HER2 negative metastatic breast cancer with loss of estrogen and progesterone receptors.PMID 42673686Read ↗

ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).Semantic proximity Read ↗

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read ↗

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.Semantic proximity Read ↗

Genetic and clinical landscape of ER + /PR- breast cancer in China.Semantic proximity Read ↗

ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Semantic proximity Read ↗

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.Semantic proximity Read ↗

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.Semantic proximity Read ↗

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.Semantic proximity Read ↗

HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumorsSemantic proximity Read ↗

Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumoursSemantic proximity Read ↗

Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.Semantic proximity Read ↗

The Present and Future of Clinical Management in Metastatic Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.